Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 2, pp 169–177

Mycobacterium Tuberculosis, Autoimmunity, and Vitamin D

Authors

  • Yinon Shapira
    • Center for Autoimmune DiseasesChaim Sheba Medical Center
  • Nancy Agmon-Levin
    • Center for Autoimmune DiseasesChaim Sheba Medical Center
    • Department of Medicine ‘B’Chaim Sheba Medical Center
    • Center for Autoimmune DiseasesChaim Sheba Medical Center
    • Department of Medicine ‘B’Chaim Sheba Medical Center
    • Sackler Faculty of MedicineTel-Aviv University
Article

DOI: 10.1007/s12016-009-8150-1

Cite this article as:
Shapira, Y., Agmon-Levin, N. & Shoenfeld, Y. Clinic Rev Allerg Immunol (2010) 38: 169. doi:10.1007/s12016-009-8150-1

Abstract

Mycobacterium tuberculosis (TB) is a major cause of morbidity and mortality worldwide. Current anti-TB chemotherapies, although effective, are associated with side effects and are limited in treating drug-resistant strands. Autoimmune diseases are a leading cause of morbidity and mortality, with a growing mass of evidence implicating infections (e.g., TB) as their triggers. The burden of TB might further increase by reactivation threats hovering over millions harboring latent infection, thus, calling for novel approaches for this dire ailment. In recent years, the non-calcemic physiological actions of vitamin D have drawn a great deal of attention. In this review, we will focus on the role of vitamin D in the innate immune defense against TB on the one hand and conversely on the immunomodulatory effects of vitamin D on autoimmunity. Taken together, the suggested dual role of vitamin D in treating TB infection and possibly preventing associated autoimmunity will constitute the basis of the current review.

Keywords

Mycobacterium tuberculosisVitamin DVitamin D receptorInnate immunityAutoimmune diseaseTB

Copyright information

© Humana Press Inc. 2009